His weak grasp of evidence law and the Rules of Civil Procedure led to considerable time and effort
spent by opposing counsel to address matters (for example, the testimony of «experts» that the court ultimately refused to qualify as experts) that never amounted to anything.
As a brief overview, the Management and Board have embarked upon a failed merger that garnered virtually no support from its shareholders, and was
opposed by ISS, and continued on that path until the date of the special shareholders meeting and scheduled vote,
spending lavishly in a failed effort to close it; attempted to implement substantial new options to itself, a plan
opposed by ISS and the shareholders, which was withdrawn; continually paid itself outrageous sums of the shareholders money over the past three years; rejected highly qualified outside board members with deep, broad healthcare company experience supported
by its shareholders; held many Board and Committee meetings with nothing to show for it; formed a new Strategic Transactions Committee that is highly paid but that has produced no deals for the shareholders to consider or for any outside valuation experts to formally review;
spent lavishly on accountants, auditors and
counsel; failed to successfully hire any outside professional negotiators and finally extinguish or remove the outstanding lease obligations; distributed no cash to the shareholders despite holding excess amounts; formed no special purpose entity to hold any royalty and milestone rights and payments for the benefit of its shareholders; and thus generally failed in its fiduciary duties to shareholders.